Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Prior treatment

• Subject received any investigational/experimental drug, biologic, or device within 30 days before baseline, with the exception of migalastat
• Subject anticipated starting gene therapy during the study period
• Subject required treatment with Replagal® (agalsidase alfa) or Fabrazyme® (agalsidase beta)
• Subject required treatment with Glyset® (miglitol) or Zavesca® (miglustat)

Other illness

• Subject had advanced kidney disease requiring dialysis or kidney transplantation
• Subject had any intercurrent illness or condition at Visit 1 that may have precluded the subject from fulfilling the protocol requirements or suggested to the investigator that the potential subject may have an unacceptable risk by participating in this study
• Subject had a history of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol)

Lab values

• Subject's last available estimated glomerular filtration rate (eGFR) in the previous study was \< 60 mL/min/1.73 m2

Other

• Female subject was pregnant or breast-feeding, or was planning to become pregnant during the study period
• In the opinion of the investigator, the subject and/or parent or legally-authorized representative was unlikely or unable to comply with the study requirements

• Male or female subjects diagnosed with Fabry disease \> 12 years of age who completed Study AT1001-020
• Subject's parent or legally-authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of personal health information or research-related health information, and subject provides assent, if applicable
• If of reproductive potential, both male and female subjects agreed to use a medically accepted method of contraception throughout the duration of the study and for up to 30 days after their last dose of migalastat